Arkolith/Insider Trading/NRIX/Form 4

Hansen Gwenn

Chief Scientific OfficerNurix Therapeutics, Inc. (NRIX) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)31K$0.84$26K115K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)31K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001817160-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML